An evaluation is requested for a 65-year-old man in the intensive care unit who developed … — USMLE Step 2 CK

An evaluation is requested for a $65$ -year-old man in the intensive care unit who developed right calf swelling and tenderness this morning. $6$ days ago, he underwent an exploratory laparotomy with a small bowel resection for acute mesenteric ischemia. His postoperative course has been complicated by severe acute kidney injury secondary to prolonged intraoperative hypotension, though he remains nonoliguric. Since admission, he has been receiving subcutaneous unfractionated heparin for deep venous thrombosis prophylaxis.

His temperature is $37.7^\circ\text{C}$ ( $99.9^\circ\text{F}$ ), blood pressure is $135/85$ mm Hg, pulse is $98$ /min, and respirations are $16$ /min. Physical examination reveals pitting edema and tenderness over the right calf. The laparotomy incision is clean, dry, and intact.

Laboratory results today:
Hemoglobin: $11.2$ g/dL
Platelet count: $85,000/\text{mm}^3$ (preoperative: $250,000/\text{mm}^3$ )
Leukocyte count: $9,500/\text{mm}^3$
Blood urea nitrogen: $48$ mg/dL
Serum creatinine: $3.4$ mg/dL

A compression ultrasonography of the right lower extremity confirms a new deep venous thrombosis in the popliteal vein. Which of the following is the most appropriate next step in the management of this patient?

A
Discontinue unfractionated heparin and initiate fondaparinux
B
Order a heparin-platelet factor 4 antibody assay and continue current therapy pending results
C
Discontinue unfractionated heparin and initiate warfarin
Discontinue unfractionated heparin and initiate an argatroban infusionAnswer
E
Obtain blood cultures and initiate empiric broad-spectrum antibiotics

Answer

Discontinue unfractionated heparin and initiate an argatroban infusion

The correct answer involves immediately stopping all heparin products and starting an argatroban infusion. This patient developed a new deep venous thrombosis (DVT) and a

>50\%

drop in platelet count (from

250,000

85,000/\text{mm}^3

)

6

days after starting unfractionated heparin. This presentation is highly suspicious for Heparin-Induced Thrombocytopenia (HIT), a life-threatening prothrombotic state caused by IgG autoantibodies directed against the heparin-platelet factor 4 (PF4) complex. The '4Ts' score is high, indicating that immediate cessation of heparin and initiation of a non-heparin anticoagulant is mandatory. Because this patient has a significantly elevated serum creatinine (

3.4

mg/dL) indicating severe acute kidney injury, argatroban is the safest choice. Argatroban is a direct thrombin inhibitor that undergoes exclusively hepatic metabolism, avoiding toxic accumulation in renal failure.

Step-by-Step Solution

Calculate the 4Ts score to determine the clinical probability of Heparin-Induced Thrombocytopenia (HIT).

The score is high based on: Thrombocytopenia (drop > 50%), Timing (6 days), Thrombosis (new popliteal DVT), and absence of other clear causes.

A high 4Ts score necessitates immediate empiric intervention before laboratory confirmation is obtained.

Identify the immediate necessary intervention for suspected HIT.

All heparin products must be discontinued immediately, and a non-heparin anticoagulant must be started to prevent catastrophic thrombosis.

Continuing heparin or simply stopping it without starting an alternative agent leaves the patient at an unacceptably high risk for massive thrombosis.

Select the appropriate alternative anticoagulant based on patient comorbidities.

The patient has severe acute kidney injury (creatinine 3.4 mg/dL). Therefore, argatroban is selected over fondaparinux or bivalirudin.

Argatroban undergoes hepatic clearance and is safe in renal failure, whereas fondaparinux and bivalirudin are renally cleared and contraindicated in this setting.

Key Concept

Patients with highly probable Heparin-Induced Thrombocytopenia (HIT) require immediate cessation of all heparin and initiation of a non-heparin anticoagulant. In the setting of severe renal impairment, the direct thrombin inhibitor argatroban is the agent of choice due to its hepatic clearance.

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic